- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03934359
A Study to Evaluate the Safety, Tolerability of DN1508052-01 in Advanced Solid Tumors
A Phase Ⅰ, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of DN1508052-01 as a Single Agent When Administered Subcutaneously to Adult Patients With Advanced Solid Tumors
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
La Jolla, California, United States, 92093
- University of California San Diego-Moores Cancer Center
-
-
Missouri
-
Saint Louis, Missouri, United States, 20237
- Washington University School of Medicine - Siteman Cancer Center
-
-
Washington
-
Seattle, Washington, United States, 98109
- University of Washington - Seattle Cancer Care Alliance
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 years or older;
- Patients with histologically or cytologically confirmed, unresectable advanced solid tumors that have progressed despite standard therapy or for which no standard therapy exists;
- Patients must have at least one measurable lesion as defined by RECIST v1.1;
- ECOG performance score 0 or 1;
- Life expectancy ≥ 3 months;
Patients who have sufficient Baseline organ function and whose laboratory data meet the following criteria at enrollment:
- Absolute neutrophil count (ANC)≥1.5 × 109/L;
- Platelets ≥100 × 109/L;
- Hemoglobin ≥90g/dL;
Liver function:
Serum bilirubin ≤1.5 × upper limit of normal (ULN) or ≤ 3×ULN in any subject with Gilbert's Syndrome; Aspartate aminotransferase(AST) and alanine aminotransferase(ALT) ≤2.5 × ULN without liver metastases, or ≤5 × ULN if the patient has documented liver metastases;
- International normalization ratio ≤1.2 if the patient is not on anticoagulants, or ≤3 if the patient is on anticoagulants;
- Serum creatinine ≤1.5 mg/dL, or estimated glomerular filtration rate (eGFR)≥60 mL/min/1.73 m2;
- Women of childbearing potential must have a negative serum pregnancy test prior to study entry, and agree to use adequate contraception from study entry through at least 1 month after the last dose of study drug. A female patient of nonchildbearing potential will have had at least 12 continuous months of natural (spontaneous) amenorrhea, follicle stimulating hormone level ≥40 mIU/mL at Screening, and an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms), or have had surgical bilateral oophorectomy, hysterectomy, or tubal ligation ≥6 weeks prior to Screening; in the case of oophorectomy alone, reproductive status will be confirmed by hormone level assessment;
- A male patient must agree to use adequate contraception (male condom with spermicide or provide evidence of successful vasectomy; sterile sexual partner; or female sexual partner who uses an intrauterine device with spermicide, a female condom with spermicide, a contraceptive sponge with spermicide, an intravaginal system, a double diaphragm with spermicide, a cervical cap with spermicide) from study entry through at least 1 month after the last dose of study drug;
- Patients must provide written informed consent prior to any study procedures.
Exclusion Criteria:
Disease
Patients with symptomatic central nervous system (CNS) metastases or carcinomatous meningitis; Note: Patients with treated CNS metastases may participate in this trial if the patient has completed radiotherapy or surgery for CNS metastases >2 weeks prior to study entry and if the patient is neurologically stable ≥ 2 weeks (no new neurologic deficits from brain metastasis on Screening clinical examination, no new findings on CNS imaging, and no corticosteroids being used).
Medical Conditions
- Patients who have a history of another primary malignancy, with the exception of locally excised non-melanoma skin cancer and carcinoma in situ of uterine cervix. A patient who has had no evidence of disease from another primary cancer for 3 or more years is allowed to participate in the study;
- Patients who have a known history of active hepatitis C or chronic hepatitis B ("active hepatitis" defined as HCV RNA level ≥ 103 copies/mL for hepatitis C or HBV DNA level ≥ 104 copies/mL for hepatitis B at Screening);
- Patients who have a known diagnosis of human immunodeficiency virus (HIV);
Patients who have any severe and/or uncontrolled medical conditions or other conditions that, in the opinion of the Investigator and Sponsor, could affect the patient's participation in the study such as:
- Uncontrolled diabetes mellitus, HbA1c≥8%;
- Malignant illnesses that are uncontrolled or whose control may be jeopardized by treatment with this study treatment;
- Moderate or severe hepatic impairment, i.e., Child-Pugh class B or C (see appendix 8.6);
- Autoimmune disorders with systemic therapy;
- Patients who with an allo-transplant of any kind (including those with a xenograft heart valve);
Any significant ophthalmologic abnormality, including but not limited to the following:
- Grade 2 or greater severity syndrome of dry eye;
- Keratoconjunctivitis sicca;
- Sjogren's syndrome;
- Iritis;
- Patients who have a history of definite neurological disorders that affected brain function activity, including epilepsy or dementia;
- Active infections requiring antibiotic intravenous therapy at Screening;
- Pregnancy or lactation;
- Patients with any comorbid medical disorder that, in the opinion of the Investigator or Sponsor, may increase the risk of toxicity; Organ Function and Laboratory Values
Patients who have impaired cardiac function or clinically significant cardiac diseases, including any of the following:
- Baseline QT interval corrected for heart rate using Fridericia's formula >480 msec or congenital long QT syndrome;
- Concomitant diseases that could prolong the QT interval, as assessed by the Investigator, such as autonomic neuropathy (caused by diabetes or Parkinson's disease), cirrhosis, uncontrolled hypothyroidism, or grade 3 or greater severity electrolyte abnormality (CTCAE v5.0);
- Concomitant medications known to prolong the QT interval;
- History or presence of serious uncontrolled ventricular arrhythmias;
- Left ventricular ejection fraction <50% assessed by echocardiogram;
- Any of the following within 3 months prior to the first dose of study medication: myocardial infarction, severe/unstable angina, coronary artery bypass graft, congestive heart failure, cerebrovascular accident, or transient ischemic attack;
- Other clinically significant heart disease such as congestive heart failure NYHA Class Ⅱ or greater severity and requiring heart transplant or uncontrolled hypertension (systolic blood pressure > 150 mmHg or diastolic blood pressure > 100 mmHg, in spite of antihypertensive medication); Prior Therapy
- Chemotherapy, biologic therapy, herbal therapy, radiotherapy or investigational agents within 5 half lives or within 4 weeks (whichever is longer) prior to administration of the first dose of study drug on Day 1 or have not recovered to grade 1 or below from the side effects of such therapy (excluding cases of alopecia);
- Patients received potent CYP3A4 inducer or inhibitor within 2 weeks prior to administration of the first dose of study drug on Day 1.
- Patients received systemic corticosteroids within 2 weeks prior to administration of the first dose of study drug on Day 1.
- Major surgery for any cause within 4 weeks of first dosing;
- Treated with immunomodulator (e.g., motolimod, GS9688, IMO4200, E-6742, E-6887, etc).
- Patients who have a history of allergic reactions (significant urticaria, angioedema, anaphylaxis) attributed to compounds of similar chemical or biologic composition to DN1508052-01; Patients with scheduled surgeries or who are, in the Investigator's opinion, likely to require surgery.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the maximum tolerated dose (MTD)
Time Frame: 28 days
|
MTD is the highest dose of DN1508052-01 in subjects with DLT less than 33.3% during the DLT observation in the dose escalation
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: Up to 24 months
|
Assessment of the cidence and severity of treatment-related AEs in who received at least 1 dose of in DN1508052-01
|
Up to 24 months
|
Time to peak (Tmax) of plasma concentration
Time Frame: Up to 2 months
|
Pharmacokinetics profile of DN1508052-01 :Time to peak (Tmax) of plasma concentration
|
Up to 2 months
|
Maximum plasma concentration (Cmax)
Time Frame: Up to 2 months
|
Pharmacokinetics profile of DN1508052-01 : Maximum plasma concentration (Cmax)
|
Up to 2 months
|
Halflife (T1/2)
Time Frame: Up to 2 months
|
Pharmacokinetics profile of DN1508052-01 : Halflife (T1/2)
|
Up to 2 months
|
Clearance/ bioavailability (CL/F)
Time Frame: Up to 2 months
|
Pharmacokinetics profile of DN1508052-01 : Clearance/ bioavailability (CL/F)
|
Up to 2 months
|
Area under curve (AUC)
Time Frame: Up to 2 months
|
Pharmacokinetics profile of DN1508052-01 : Area under curve (AUC)
|
Up to 2 months
|
Efficacy Assessments
Time Frame: Up to 24 months
|
Subjects will be assessed using RECIST v1.1.
The primary aim is to demonstrate clinically meaning in ORR
|
Up to 24 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DN1508052-01-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Genentech, Inc.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsCanada, Korea, Republic of, United States, Brazil, Australia, Argentina, Spain, New Zealand, Poland
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors, Neoplasms, Advanced SolidHungary
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
Clinical Trials on DN1508052-01
-
Livzon Pharmaceutical Group Inc.Active, not recruiting
-
Zucara Therapeutics Inc.RecruitingType 1 Diabetes Mellitus With HypoglycemiaUnited States, Canada
-
Ixchelsis LimitedCompletedPremature EjaculationUnited States
-
Enterin Inc.TerminatedParkinson Disease | ConstipationUnited States
-
Shanghai Hongyitang Biopharmaceutical Technology...Completed
-
Zhongmou TherapeuticsRecruitingX-linked RetinoschisisChina
-
BioPharmX, Inc.CompletedAcne VulgarisUnited States
-
Enterin Inc.CompletedParkinson Disease | ConstipationUnited States
-
Hokkaido University HospitalJapan Agency for Medical Research and DevelopmentRecruiting
-
Valerio TherapeuticsRecruitingBreast Cancer | Prostate Cancer | Advanced or Metastatic Solid Tumors | Recurrent Ovarian CancerUnited States